Fulcrum Therapeutics Q2 EPS Totals $0.87 Compared With $(0.38) Loss YoY, Company Exits Quarter With Cash And Equivalents Worth $273.8M
Portfolio Pulse from Benzinga Newsdesk
Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 earnings of $0.87 per share, a significant improvement from a $(0.38) loss YoY. However, the company missed sales estimates by 99.71%, reporting $80,000 in sales compared to the expected $27.66 million. The company exits the quarter with $273.8 million in cash and equivalents.
July 31, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fulcrum Therapeutics reported a significant improvement in EPS for Q2, but missed sales estimates by a wide margin. The company has a strong cash position.
While the significant improvement in EPS is positive, the massive miss on sales estimates and the sharp decline in sales YoY are concerning. The strong cash position provides some stability, but the mixed results are likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100